Literature DB >> 7933226

The early detection and treatment of prostate cancer: the perspective of the Canadian Task Force on the Periodic Health Examination.

J W Feightner1.   

Abstract

Few would challenge the important health burden associated with prostate cancer. This concern, combined with the emergence of a biochemical test that has the potential for early detection, has fueled enthusiasm for concerted efforts aimed at early detection and treatment of prostate cancer. Reflecting the approach and perspective of the Canadian Task Force on the Periodic Health Examination, this report argues for the objective evaluation of evidence to address the question of whether to initiate and promote early detection campaigns for prostate cancer. Specifically, 3 questions are addressed: "what is the goal of early detection?", "how should the existing evidence be evaluated?" and "how should evidence guide our actions and policies?". After reviewing the evidence using its standardized rules of evidence, the Canadian Task Force has concluded that there presently is insufficient evidence to promote the early detection of prostate cancer in asymptomatic men.

Entities:  

Mesh:

Year:  1994        PMID: 7933226     DOI: 10.1016/s0022-5347(17)32360-1

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  3 in total

Review 1.  Prostate-specific antigen in the early detection of prostate cancer.

Authors:  Ian M Thompson; Donna P Ankerst
Journal:  CMAJ       Date:  2007-06-19       Impact factor: 8.262

2.  Challenging the 10-year rule: The accuracy of patient life expectancy predictions by physicians in relation to prostate cancer management.

Authors:  Kevin M Y B Leung; Wilma M Hopman; Jun Kawakami
Journal:  Can Urol Assoc J       Date:  2012-10       Impact factor: 1.862

3.  Effect of Perceived Self-Vulnerability on Prostate Cancer Screening Uptake and Associated Factors: A Cross-Sectional Study of Public Health Facilities in Western Kenya.

Authors:  Charles Oduor Opondo; Patrick Ogola Onyango; Collins Otieno Asweto
Journal:  Ann Glob Health       Date:  2022-02-17       Impact factor: 2.462

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.